重磅首发单细胞光流控分选仪，追光生物击碎“价格&性能2选1”时代

Core Viewpoint - The launch of the OptoBot 1000 series by Chasing Light Biotechnology represents a significant breakthrough in the domestic high-end life science instrument sector, integrating advanced technologies such as optical tweezers, microfluidics, and biochips for high-throughput single-cell sorting [2][7]. Product Overview - The OptoBot 1000 series combines six traditional laboratory devices, including a single-cell printer and flow cytometer, into a fully automated system enhanced by AI software, allowing for clean and efficient operations [7]. - The device can culture cells or microorganisms on a chip for seven days and complete single-cell sorting in a short time, with capabilities to correlate cell phenotype data with sequencing data [7]. - The product has been tested in a key laboratory at Sichuan University since August 2023, showcasing rapid development and deployment [7]. Technological Innovation - The OptoBot 1000 series is noted for its disruptive innovation, significantly reducing the time required for single-cell sorting from traditional methods to as little as one week [8]. - The technology utilizes a non-damaging optical field to sort cells, maintaining high cell viability and suitability for subsequent experiments [19]. - The product's pricing is approximately one-third of foreign competitors, making it more accessible for users [20]. Market Potential - The OptoBot 1000 series is expected to enhance the efficiency of antibody drug and cell/gene therapy development, indicating substantial commercial prospects [10]. - The product is positioned to shift China's life science instruments from a "follower" to a "leader" in the global market [10]. Strategic Collaborations - Chasing Light Biotechnology has established strategic partnerships with companies like BGI Genomics to integrate sequencing capabilities with their instruments, creating a comprehensive ecosystem for drug development [23]. - The company is supported by a strong management and R&D team with extensive experience in the medical device sector, enhancing its potential for commercialization [22]. Investment Insights - Investors view the OptoBot 1000 series as a key player in breaking the long-standing dominance of imported brands in the high-end life science instrument market [26]. - The current market environment is seen as a golden opportunity for the development of domestic high-end life science instruments, with significant backing from national policies and market demand [26].